Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Work In Process (2018 - 2024)

IGC Pharma has reported Work In Process over the past 7 years, most recently at $2000.0 for Q3 2024.

  • Quarterly Work In Process fell 81.82% to $2000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Sep 2024, down 81.82% year-over-year, with the annual reading at $18000.0 for FY2023, 96.92% down from the prior year.
  • Work In Process was $2000.0 for Q3 2024 at IGC Pharma, down from $36000.0 in the prior quarter.
  • Over five years, Work In Process peaked at $3.9 million in Q3 2020 and troughed at $2000.0 in Q3 2024.
  • The 5-year median for Work In Process is $2.2 million (2020), against an average of $1.7 million.
  • Year-over-year, Work In Process surged 1397.18% in 2020 and then crashed 96.92% in 2023.
  • A 5-year view of Work In Process shows it stood at $2.2 million in 2020, then rose by 0.41% to $2.2 million in 2021, then crashed by 71.56% to $628000.0 in 2022, then tumbled by 98.25% to $11000.0 in 2023, then plummeted by 81.82% to $2000.0 in 2024.
  • Per Business Quant, the three most recent readings for IGC's Work In Process are $2000.0 (Q3 2024), $36000.0 (Q2 2024), and $11000.0 (Q3 2023).